| About the author: |
O. M. Bilovol, I. I. Kniazkova, N. V. Kuzminova, O. M. Kirienko, L. P. Abramova, A. O. Gavrylyuk |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of our research was to increase the effectiveness of the therapy of the patients with hypertension and metabolic syndrome. 56 patients with hypertension, and metabolic syndrome were examined. After registration of the baseline data in addition to baseline therapy Quercetinum 40 mg 3 times a day for 2 months was administered to 30 patients (group 1). Basic therapy was administered to 26 patients (group 2). After treatment in group 1, the levels of office systolic and diastolic blood pressure were 7.6 % and 6.9 % (p<0.05), and the average daily systolic and diastolic blood pressure (according to daily blood pressure monitoring) were 8.6 % and 8.1 % (p<0.05) lower than in group 2. In group 1 positive changes in lipid and carbohydrate metabolism were registered. It was found that the decline of tumor necrosis factor-α levels in group 1 were significantly higher (38.6 %, р<0.05) than in group 2 (20.6 %, р<0.05). Group 1 patients showed significantly decreased of malonic dialdehyde (Δ-37.5 % vs Δ-15.7 % in group 2, р<0,05) and increased of superoxide dismutase activity (Δ30.4 % vs 9.0 %, respectively, р<0.05). Thus, addition of Quercetinum to patients with hypertension and metabolic syndrome increases the efficacy of antihypertensive therapy, positively affects on glucometabolic parameters, plasma levels of tumor necrosis factor-α and antioxidant status. |
| Tags |
hypertension, metabolic syndrome, lipid peroxidation, tumor necrosis factor-α, quercetin |
| Bibliography |
- Mankovskyi B. Insulinoterapiya: doza maie znachennia. Diabet. Ozhyrinnia. Metabolichnyi syndrom. 2020; 2. (9):27–32.[in Ukrainian]
- Reznik E.V., Nikitin I.G. Hypertension management in metabolic syndrome. The Russian Archives of Internal Medicine. 2019; 9(5):327–347. https://doi.org/10. 20514/2226-6704-2019-9-5-327-347 [in Russian]
- Sirenko JM. Recomendatsii ESC I ESH z likuvannia arterialnoyi hipertenziyi. Kyiv: Zaslavskyi OYu; 2019. 204 s. [in Ukrainian]
- D'Andrea G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia. 2015; 106:256–71. doi: 10.1016/j.fitote.2015.09.018.
- Drawz PE, Beddhu S, Kramer HJ, Rakotz M, Rocco MV, Whelton PK. Blood Pressure Measurement: A KDOQI Perspective. Am J Kidney Dis. 2020; 75(3):426–434. doi: 10.1053/j.ajkd.2019.08.030
- Hernandez-Baixauli J, Quesada-Vazquez S, Marine-Casado R, Cardoso KG, Caimari A,delBas JM. et al. Detection of early disease risk factors associated with metabolic syndrome: a new era with the NMR metabolomics assessment. Nutrients. 2020; 12 (3): 806. doi: 10.3390/nu12030806
- Kang YE, Kim JM, Joung KH, Lee JH, You BR, Choi MJ, et al. The Roles of Adipokines, Proinflammatory Cytokines, and Adipose Tissue Macrophages in Obesity-Associated Insulin Resistance in Modest Obesity and Early Metabolic Dysfunction. PLoS One. 2016; 11(4):.e0154003. doi: 10.1371/journal.pone.0154003.
- Martín-Bórnez M, Galeano-Otero I, Del Toro R, Smani T. TRPC and TRPV Channels' Role in Vascular Remodeling and Disease. Int J Mol Sci. 2020; 21(17):6125. doi: 10.3390/ijms21176125.
- Mohammadi M, Gozashti MH, Aghadavood M, Mehdizadeh MR, Hayatbakhsh MM. Clinical Significance of Serum IL-6 and TNF-α Levels in Patients With Metabolic Syndrome. Rep Biochem Mol Biol. 2017; 6(1):74–79.
- Parkhomenko A, Kozhukhov S, Lutay Y. Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patientswith ST-elevation acute myocardial infarction. European Heart Journal. 2018; 39(S1): 431. doi: 10. .1093/ eurheartj/ehy565.2152
- Pickering RJ, Rosado CJ, Sharma A, Buksh S, Tate M, de Haan JB. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. Clinical & Translational Immunology. 2018; 7:1–20.
- Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Curr Hypertens Rep. 2018; 20(2):12. doi: 10.1007/s11906-018-0812-z.
- Sattar N, Gill JMR, Alazawi W. Improving prevention strategies for cardiometabolic disease. Nat Med. 2020; 26(3):320–-325. doi: 10.1038/s41591-020-0786-7.
- Senoner T, Dichtl W. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients. 2019; 11(9):2090.
|
| Publication of the article |
«World of Medicine and Biology» №1(75), 2021 year, 018-022 pages, index UDK 616.12-008.331.1-085:616-008.9 |
| DOI |
10.26724/2079-8334-2021-1-75-18-22 |
